Sotatercept significantly reduces pulmonary vascular resistance in patients with CpcPH–HFpEF compared with placebo, according to a trial.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Among adults with pulmonary arterial hypertension, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A previous study found that seralutinib lowered ...

WASHINGTON -- The novel investigational therapy seralutinib effectively reduced pulmonary vascular resistance (PVR) in patients with pulmonary arterial hypertension (PAH) on standard background ...

In adults with Fontan circulation, a higher pulmonary vascular resistance index (PVRI) during exercise and failure to reduce the PVRI were associated with a greater risk for death or heart ...

Drugs currently marketed for pulmonary arterial hypertension have been able to extend the lives of patients but have shown limitations in their ability to prevent or reverse the disease. A novel ...